MX2024006709A - Composiciones y metodos para el tratamiento de epilepsias. - Google Patents
Composiciones y metodos para el tratamiento de epilepsias.Info
- Publication number
- MX2024006709A MX2024006709A MX2024006709A MX2024006709A MX2024006709A MX 2024006709 A MX2024006709 A MX 2024006709A MX 2024006709 A MX2024006709 A MX 2024006709A MX 2024006709 A MX2024006709 A MX 2024006709A MX 2024006709 A MX2024006709 A MX 2024006709A
- Authority
- MX
- Mexico
- Prior art keywords
- branched
- sirna
- molecules
- sirna molecules
- interfering rna
- Prior art date
Links
- 206010015037 epilepsy Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
- 230000002452 interceptive effect Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 208000024658 Epilepsy syndrome Diseases 0.000 abstract 1
- 208000002877 Epileptic Syndromes Diseases 0.000 abstract 1
- 101000944018 Homo sapiens Potassium channel subfamily T member 1 Proteins 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 102100033508 Potassium channel subfamily T member 1 Human genes 0.000 abstract 1
- 108091022021 Sodium-Activated Potassium Channels Proteins 0.000 abstract 1
- 102000025233 Sodium-Activated Potassium Channels Human genes 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284932P | 2021-12-01 | 2021-12-01 | |
| PCT/US2022/080766 WO2023102490A1 (en) | 2021-12-01 | 2022-12-01 | Compositions and methods for treatment of epilepsies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006709A true MX2024006709A (es) | 2024-08-19 |
Family
ID=86613118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006709A MX2024006709A (es) | 2021-12-01 | 2022-12-01 | Composiciones y metodos para el tratamiento de epilepsias. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4441229A1 (https=) |
| JP (1) | JP2024542728A (https=) |
| KR (1) | KR20240159663A (https=) |
| CN (1) | CN118974255A (https=) |
| AU (1) | AU2022402159A1 (https=) |
| CA (1) | CA3241122A1 (https=) |
| MX (1) | MX2024006709A (https=) |
| WO (1) | WO2023102490A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019218987B2 (en) * | 2018-02-12 | 2025-04-24 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| US20220056455A1 (en) * | 2018-12-20 | 2022-02-24 | Praxis Precision Medicines, Inc. | Compositions and methods for the treatment of kcnt1 related disorders |
| PE20220168A1 (es) * | 2019-03-15 | 2022-01-28 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir la expresion de kcnt1 |
-
2022
- 2022-12-01 MX MX2024006709A patent/MX2024006709A/es unknown
- 2022-12-01 KR KR1020247021913A patent/KR20240159663A/ko active Pending
- 2022-12-01 AU AU2022402159A patent/AU2022402159A1/en active Pending
- 2022-12-01 CA CA3241122A patent/CA3241122A1/en active Pending
- 2022-12-01 CN CN202280090018.8A patent/CN118974255A/zh active Pending
- 2022-12-01 JP JP2024532709A patent/JP2024542728A/ja active Pending
- 2022-12-01 WO PCT/US2022/080766 patent/WO2023102490A1/en not_active Ceased
- 2022-12-01 EP EP22902402.1A patent/EP4441229A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240159663A (ko) | 2024-11-05 |
| AU2022402159A1 (en) | 2024-07-11 |
| WO2023102490A8 (en) | 2023-09-14 |
| WO2023102490A1 (en) | 2023-06-08 |
| CA3241122A1 (en) | 2023-06-08 |
| JP2024542728A (ja) | 2024-11-15 |
| CN118974255A (zh) | 2024-11-15 |
| EP4441229A1 (en) | 2024-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012126A (es) | Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central. | |
| MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
| MX2023010958A (es) | Agentes de arn modificados con efecto reducido fuera de la diana. | |
| MX2023008469A (es) | Oligonucleotidos de doble hebra modificados. | |
| MX2021014769A (es) | Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos. | |
| MX2025003674A (es) | Composiciones de arnip y metodos dirigidos a acidos nucleicos de la proteina tau asociada a microtubulos | |
| AR123420A1 (es) | Inhibidores de dux4 y métodos de uso de estos | |
| WO2019217397A3 (en) | Compositions and methods for improving strand biased | |
| BR112018008344A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição | |
| MY203259A (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| BR112022021813A2 (pt) | Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas | |
| MX2024000277A (es) | Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer. | |
| WO2023283403A3 (en) | Bis-rnai compounds for cns delivery | |
| MX2024006649A (es) | Composiciones y metodos para el tratamiento del dolor. | |
| MX2025003632A (es) | Composiciones de arnip y metodos dirigidos a acidos nucleicos de alfa-sinucleina | |
| MX2024006709A (es) | Composiciones y metodos para el tratamiento de epilepsias. | |
| WO2024073589A8 (en) | Compositions and methods for treatment of neuroinflammatory diseases | |
| WO2021262919A3 (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| WO2024073604A3 (en) | Compositions and methods for treatment of neurodegenerative diseases | |
| MX2025003636A (es) | Composiciones y metodos para el tratamiento de la enfermedad de huntington | |
| WO2024073592A3 (en) | Compositions and methods for treatment of neurological disorders | |
| BR112022005028A2 (pt) | Molécula de ácido nucleico para tratamento de trombocitopenia e uso da mesma | |
| WO2024073596A3 (en) | Compositions and methods for treatment of spinocerebellar ataxias | |
| WO2023225495A3 (en) | Compositions and methods for treatment of microsatellite dna expansion disorders | |
| WO2024073603A3 (en) | Compositions and methods for treatment of neuroinflammatory diseases |